Natco Pharma

Natco Pharma
Natco Pharma
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
  • Shareholder Return
    529%
  • Sales Growth
    41%
  • Return on Equity
    22 %

Why Super 50

Founded in 1981 by VC Nannapaneni, the Hyderabad-based drugmaker has a niche focus on oncology in which it controls a quarter of the domestic market. It has restricted its focus on developed markets to sell complex generics and partnered with other pharma companies to mitigate development and litigation-related risks. As it expands its business across new therapeutic areas such as Hepatitis C and cardio-diabetology, the Street believes Natco is well-placed to counter macro headwinds facing the pharma sector.



More Stories